This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tai, C. Y.
Right arrow Articles by Mendel, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tai, C. Y.
Right arrow Articles by Mendel, D. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3234-3241, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071

Chun Y. Tai,1 Paul A. Escarpe,1 Robert W. Sidwell,2 Matthew A. Williams,3 Willard Lew,3 Huiwei Wu,3 Choung U. Kim,3 and Dirk B. Mendel1,*

Research Virology1 and Medicinal Chemistry,3 Gilead Sciences, Inc., Foster City, California 94404, and Institute for Antiviral Research, Utah State University, Logan, Utah 84322-56002

Received 7 April 1998/Returned for modification 3 June 1998/Accepted 3 October 1998

An oral prodrug of GS 4071, a potent and selective inhibitor of influenza neuraminidases, is currently under clinical development for the treatment and prophylaxis of influenza virus infections in humans. To investigate the potential development of resistance during the clinical use of this compound, variants of the human influenza A/Victoria/3/75 (H3N2) virus with reduced susceptibility to the neuraminidase inhibitor GS 4071 were selected in vitro by passaging the virus in MDCK cells in the presence of inhibitor. After eight passages, variants containing two amino acid substitutions in the hemagglutinin (A28T in HA1 and R124M in HA2) but no changes in the neuraminidase were isolated. These variants exhibited a 10-fold reduction in susceptibility to GS 4071 and zanamivir (GG167) in an in vitro plaque reduction assay. After 12 passages, a second variant containing these hemagglutinin mutations and a Lys substitution for the conserved Arg292 of the neuraminidase was isolated. The mutant neuraminidase enzyme exhibited high-level (30,000-fold) resistance to GS 4071, but only moderate (30-fold) resistance to zanamivir and 4-amino-Neu5Ac2en, the amino analog of zanamivir. The mutant enzyme had weaker affinity for the fluorogenic substrate 2'-(4-methylumbelliferyl)-alpha -D-N-acetylneuraminic acid and lower enzymatic activity compared to the wild-type enzyme. The viral variant containing the mutant neuraminidase did not replicate as well as the wild-type virus in culture and was 10,000-fold less infectious than the wild-type virus in a mouse model. These results suggest that although the R292K neuraminidase mutation confers high-level resistance to GS 4071 in vitro, its effect on viral virulence is likely to render this mutation of limited clinical significance.

* Corresponding author. Mailing address: Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA 94404. Phone: (650) 573-4839. Fax: (650) 573-4890. E-mail: Dirk_Mendel{at}gilead.com.

Antimicrobial Agents and Chemotherapy, December 1998, p. 3234-3241, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lee, J. H., Pascua, P. N. Q., Song, M.-S., Baek, Y. H., Kim, C.-J., Choi, H.-W., Sung, M.-H., Webby, R. J., Webster, R. G., Poo, H., Choi, Y. K. (2009). Isolation and Genetic Characterization of H5N2 Influenza Viruses from Pigs in Korea. J. Virol. 83: 4205-4215 [Abstract] [Full Text]  
  • Yen, H.-L., Ilyushina, N. A., Salomon, R., Hoffmann, E., Webster, R. G., Govorkova, E. A. (2007). Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo. J. Virol. 81: 12418-12426 [Abstract] [Full Text]  
  • Yen, H.-L., Herlocher, L. M., Hoffmann, E., Matrosovich, M. N., Monto, A. S., Webster, R. G., Govorkova, E. A. (2005). Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility. Antimicrob. Agents Chemother. 49: 4075-4084 [Abstract] [Full Text]  
  • Jackson, D., Barclay, W., Zurcher, T. (2005). Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55: 162-169 [Abstract] [Full Text]  
  • Lipatov, A. S., Govorkova, E. A., Webby, R. J., Ozaki, H., Peiris, M., Guan, Y., Poon, L., Webster, R. G. (2004). Influenza: Emergence and Control. J. Virol. 78: 8951-8959 [Full Text]  
  • Ferguson, N. M., Mallett, S., Jackson, H., Roberts, N., Ward, P. (2003). A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother 51: 977-990 [Abstract] [Full Text]  
  • Wetherall, N. T., Trivedi, T., Zeller, J., Hodges-Savola, C., McKimm-Breschkin, J. L., Zambon, M., Hayden, F. G. (2003). Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network. J. Clin. Microbiol. 41: 742-750 [Abstract] [Full Text]  
  • Wang, M. Z., Tai, C. Y., Mendel, D. B. (2002). Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir. Antimicrob. Agents Chemother. 46: 3809-3816 [Abstract] [Full Text]  
  • Tumpey, T. M., Garcia-Sastre, A., Mikulasova, A., Taubenberger, J. K., Swayne, D. E., Palese, P., Basler, C. F. (2002). Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Natl. Acad. Sci. USA 99: 13849-13854 [Abstract] [Full Text]  
  • Van Rompay, K. K. A., Matthews, T. B., Higgins, J., Canfield, D. R., Tarara, R. P., Wainberg, M. A., Schinazi, R. F., Pedersen, N. C., North, T. W. (2002). Virulence and Reduced Fitness of Simian Immunodeficiency Virus with the M184V Mutation in Reverse Transcriptase. J. Virol. 76: 6083-6092 [Abstract] [Full Text]  
  • Molla, A., Kati, W., Carrick, R., Steffy, K., Shi, Y., Montgomery, D., Gusick, N., Stoll, V. S., Stewart, K. D., Ng, T. I., Maring, C., Kempf, D. J., Kohlbrenner, W. (2002). In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675. J. Virol. 76: 5380-5386 [Abstract] [Full Text]  
  • Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K. (2002). In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705. Antimicrob. Agents Chemother. 46: 977-981 [Abstract] [Full Text]  
  • Kati, W. M., Montgomery, D., Carrick, R., Gubareva, L., Maring, C., McDaniel, K., Steffy, K., Molla, A., Hayden, F., Kempf, D., Kohlbrenner, W. (2002). In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication. Antimicrob. Agents Chemother. 46: 1014-1021 [Abstract] [Full Text]  
  • Gubareva, L. V., Webster, R. G., Hayden, F. G. (2001). Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants. Antimicrob. Agents Chemother. 45: 3403-3408 [Abstract] [Full Text]  
  • Kati, W. M., Montgomery, D., Maring, C., Stoll, V. S., Giranda, V., Chen, X., Laver, W. G., Kohlbrenner, W., Norbeck, D. W. (2001). Novel {alpha}- and {beta}-Amino Acid Inhibitors of Influenza Virus Neuraminidase. Antimicrob. Agents Chemother. 45: 2563-2570 [Abstract] [Full Text]  
  • Murrell, M. T., Porotto, M., Greengard, O., Poltoratskaia, N., Moscona, A. (2001). A Single Amino Acid Alteration in the Human Parainfluenza Virus Type 3 Hemagglutinin-Neuraminidase Glycoprotein Confers Resistance to the Inhibitory Effects of Zanamivir on Receptor Binding and Neuraminidase Activity. J. Virol. 75: 6310-6320 [Abstract] [Full Text]  
  • Snell, N. J. C. (2001). New treatments for viral respiratory tract infections--opportunities and problems. J Antimicrob Chemother 47: 251-259 [Full Text]  
  • Couch, R. B. (2000). Prevention and Treatment of Influenza. NEJM 343: 1778-1787 [Full Text]  
  • Rowley, K. V., Harvey, R., Barclay, W. S. (1999). Isolation and characterization of a transfectant influenza B virus altered in RNA segment 6. J. Gen. Virol. 80: 2353-2359 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»